ArticleAntibody therapeutics2026

The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity.

Lijun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.